Table 4.
Variables | NCPP (n = 1,027) | IP (n = 1,140) | P* |
---|---|---|---|
PT (s) | 14.06 ± 1.09 | 14.09 ± 1.83 | < 0.001 |
APTT (s) | 39.9 ± 4.5 | 39.6 ± 5.0 | 0.020 |
TT (s) | 16.9 ± 1.4 | 16.6 ± 2.0 | < 0.001 |
INR | 1.08 ± 0.11 | 1.10 ± 0.20 | 0.091 |
PTA (%) | 91 ± 11 | 92 ± 14 | < 0.001 |
FIB (g/L) | 4.71 ± 1.08 | 4.27 ± 1.18 | < 0.001 |
DD (mg/L) | 1.24 (0.65–2.75) | 1.72 (0.85–3.30) | < 0.001 |
NCPP, novel coronavirus pneumonia patients; IP, influenza patients; PT, prothrombin time; APTT, activated partial thromboplastic time; TT, thrombin time; INR, international normalized ratio; PTA, prothrombin activity; FIB, fibrinogen; DD, d-dimer
Data were presented as means ± SD or medians (25th–75th percentages)
Comparisons were performed between NCPP and IP groups using Mann-Whitney U test